The next innovation for PARP inhibitors will likely involve combinations with other DNA-damaging agents beyond just ARPIs. Promising partners include radioligands like radium (an alpha emitter) and lutetium, or even therapies like superphysiologic testosterone (BAT) that are theorized to work by inducing DNA breaks.

While BRCA2 mutations are typically associated with aggressive prostate cancer, this is not universal. Clinical experience reveals a subset of BRCA2 patients with surprisingly indolent disease, even without PARP inhibitors. This suggests other clinical or molecular factors are at play, challenging a one-size-fits-all treatment approach.

The unselected PROPEL trial showed a broad population benefit, but regulators ultimately restricted its PARP+ARPI approval to BRCA-mutated patients. This aligns with the MAGNITUDE trial, which used prospective selection and halted its non-biomarker arm for futility, validating the necessity of pre-planned genomic stratification.

Patients with BRCA-mutated prostate cancer who progress on first-line PARP inhibitors have very poor options. Standard therapies like docetaxel are largely ineffective, and emerging data suggests cross-resistance with Lutetium, creating a significant unmet clinical need for novel approaches.

When a patient has a BRCA2 mutation, clinicians on the panel view it as such a dominant predictive biomarker that they would prioritize a PARP inhibitor-based triplet regimen. This single genetic finding often outweighs other clinical factors or even the potential addition of docetaxel in treatment decisions.

Though cross-trial comparisons are imperfect, Grade 3+ anemia rates offer a stark contrast between approved PARP+ARPI combinations. The rate was 16% for olaparib+abiraterone (PROPEL) versus a much higher 49% for talazoparib+enzalutamide (TALAPRO-2). This suggests toxicity profiles should be a key factor in treatment selection.

While benefit from PARP inhibition is typically confined to core HRR genes like BRCA, the TALAPRO-2 study revealed a distinct signal for patients with CDK12 mutations. This non-canonical finding suggests a different mechanism of sensitivity and identifies a new, albeit small, patient population that may benefit from a talazoparib-enzalutamide combination.

The initial broad enthusiasm for PARP inhibitors in ovarian cancer has been refined. New data confirms a lack of overall survival improvement for patients with HRD-negative (or HR proficient) tumors, pushing clinicians toward a precision medicine approach where these drugs are reserved for patients with BRCA mutations or HRD-positive disease who are most likely to benefit.

A unique three-arm trial allowing crossover between single-agent PARP inhibitors, AR inhibitors, and a combination showed superior outcomes for the upfront combination. This suggests that "saving" a therapy for later is a suboptimal strategy for this biomarker-selected patient population.